Introduction
============

Vascular development is guided by two distinct mechanisms: Vasculogenesis, during which a primary vascular plexus is formed by angioblasts and hemopoietic cells, and angiogenesis, during which new capillaries are generated from existing blood vessels. Angiogenesis is tightly regulated by pro- and antiangiogenic molecules ([@b1-mmr-16-03-2636],[@b2-mmr-16-03-2636]) and can be divided into the following steps: Endothelial cell proliferation and migration, tube formation, vessel elongation and maturation ([@b3-mmr-16-03-2636]). Numerous factors are involved in the regulation of angiogenic processes, including the various vascular endothelial growth factor (VEGF) isoforms and their receptors (VEGFRs) ([@b4-mmr-16-03-2636],[@b5-mmr-16-03-2636]), angiopoietins (Ang1 and Ang2) and their receptors ([@b6-mmr-16-03-2636],[@b7-mmr-16-03-2636]), fibroblast growth factors ([@b8-mmr-16-03-2636]) and hypoxia-inducible factors (HIFs) ([@b9-mmr-16-03-2636]). Angiogenesis usually occurs under low O~2~ conditions; in the human placenta, angiogenesis progresses in a \~1.5--8% O~2~ environment ([@b10-mmr-16-03-2636]). HIFs are hypoxia-responsive transcription factors that act as O~2~ sensors in mammalian cells; within the HIF family, HIF1α and HIF2α have been implicated in early placental angiogenesis ([@b11-mmr-16-03-2636],[@b12-mmr-16-03-2636]).

VEGFA and placental growth factor (PlGF) are members of the VEGF family, and are critical for the regulation of angiogenesis ([@b13-mmr-16-03-2636]). The VEGFA gene can undergo alternative splicing and produce several splice variants, among which VEGF121/VEGF120, VEGF165/VEGF164 and VEGF189/VEGF188 are the most notable and stable. The various VEGFA isoforms with distinct biochemical properties may serve distinct roles during the various stages of angiogenesis ([@b14-mmr-16-03-2636]--[@b16-mmr-16-03-2636]). VEGFRs belong to the receptor tyrosine kinase family, and include VEGFR1, encoded by the FLT1 gene, VEGFR2, encoded by the KDR gene, and soluble fms-like tyrosine kinase-1 (sFlt1), an alternatively spliced form of VEGFR1, all of which have been implicated in angiogenesis ([@b17-mmr-16-03-2636]).

Peroxisome proliferator-activated receptor (PPAR)-γ belongs to the superfamily of nuclear receptors, and is a ligand-activated transcription factor predominantly expressed in adipose tissue and endothelial cells ([@b18-mmr-16-03-2636],[@b19-mmr-16-03-2636]). PPARγ has been implicated in placentation in mice, as PPARγ^−/−^ embryos exhibit severe impairments in placental vascularization, leading to increased mortality ([@b20-mmr-16-03-2636],[@b21-mmr-16-03-2636]). In addition, a role for PPARγ has been suggested during the differentiation of human labyrinthine trophoblasts, which may be associated with HIF signaling ([@b22-mmr-16-03-2636]). Furthermore, the synchronized activation of G-protein coupled receptor 120 and PPARγ has been demonstrated to enhance VEGF production in adipocytes ([@b23-mmr-16-03-2636]). Therefore, it may be hypothesized that PPARγ is implicated in porcine placental angiogenesis, and the molecular mechanisms underlying its actions involve HIF-, VEGF- and angiopoietin-mediated signaling.

Vascular endothelial cells (VECs) serve key roles in numerous physiological and pathological processes, including angiogenesis, blood pressure regulation, vascular permeability, wound healing and tumor metastasis ([@b24-mmr-16-03-2636]). PPARγ has previously been revealed to be expressed in porcine placenta, mainly localized in VECs, thus suggesting a role for PPARγ in placental vascularization ([@b25-mmr-16-03-2636]). The present study aimed to further investigate the roles of PPARγ in porcine placental vascularization and explore the molecular mechanisms involved in its actions. In the present study, VECs were isolated and incubated with PPARγ ligands to investigate the angiogenic potential of PPARγ *in vitro*. In addition, the mRNA expression levels of components of HIF- VEGF- and angiopoietin-mediated signaling pathways were also assessed.

Materials and methods
=====================

### VEC isolation and identification

All studies were approved by the Animal Care and Use Committee of Hunan Agricultural University (Hunan, China). VECs were isolated from the umbilical vein of the delivered placenta of primiparity Landrace pigs (n=16, 13 months old) as previously described ([@b26-mmr-16-03-2636],[@b27-mmr-16-03-2636]), with minor modifications. Briefly, umbilical veins were collected form delivered placenta, ligated with Serrefines (Zendainc instrument, Inc., Shanghai, China) and filled with 0.1% (w/v) collagenase (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) for digestion at 37°C 10 min. Digested cells were collected by centrifugation at 560 × g for 5 min at room temperature (RT), washed with PBS, and cultured in complete medium, which contained RPMI 1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal calf serum (Gibco; Thermo Fisher Scientific, Inc.) and 100 µg/ml penicillin/streptomycin (Gibco; Thermo Fisher Scientific, Inc.), at 37°C in a 5% CO~2~ atmosphere. Isolated VECs were cultured for three passages before identification using immunofluorescence. Cells were fixed with 4% paraformaldehyde (Sigma-Aldrich; Merck KGaA) at RT for 30 min, permeabilized with 0.1% Triton X-100 (Sigma-Aldrich; Merck KGaA) at RT for 10 min, blocked using 2% bovine serum albumin (Sigma-Aldrich; Merck KgaA) at RT for 2 h and incubated with rabbit anti-von Willebrand factor (vWF) (1:200; cat no. PB0273 Wuhan Boster Biological Technology, Ltd., Wuhan, China) and anti-cluster of differentiation (CD)31 (1:200; cat no. BA1346 Wuhan Boster Biological Technology, Ltd.) primary antibodies at 4°C overnight. Cells were then incubated with Cyanine 3-labelled Goat anti-rabbit secondary antibodies (1:100; cat no. BA1032 Wuhan Boster Biological Technology, Ltd.) at RT for 1 h, and counterstained with 0.4 µg/ml DAPI (Wuhan Boster Biological Technology, Ltd.) at RT for 10 min. Cells were incubated with rabbit immunoglobulin G (1:20; cat no. AR1010 Wuhan Boster Biological Technology, Ltd.) in place of the primary antibody to serve as the negative control. Stained cells were observed under a fluorescence microscope (Olympus Corporation, Tokyo, Japan). The positive rate of cells was determined using Image-Pro Plus software version 6.0 (Media Cybernetics, Inc., Rockville, MD, USA). Cultures between passages 3 and 6, with a positive rate of \~95% were used for further experiments.

### Cellular impedance assay

VEC proliferation was assessed using a cellular impedance assay. VECs were seeded into 8-well E-plates (ACEA Biosciences, Inc., San Diego, CA, USA) at a density of 7,500 cells/well and cultured overnight. Cells were cultured with complete medium, supplemented with 0.1% dimethyl sulfoxide (DMSO) (Sigma-Aldrich; Merck KGaA) as a control, the PPARγ agonist rosiglitazone (10 µM; Sigma-Aldrich; Merck KGaA) or the PPARγ antagonist T0070907 (15 µM; Sigma-Aldrich; Merck KGaA) respectively, as previously described ([@b28-mmr-16-03-2636],[@b29-mmr-16-03-2636]). Cellular proliferation was dynamically monitored using the iCELLigence™ real-time cell analysis (RTCA) system (ACEA Biosciences, Inc.) at 37°C in a 5% CO~2~ atmosphere for 100 h. The cell index, which reflects the adhesion, proliferation and viability of the cells through electrical impedance across interdigitated microelectrodes integrated on the bottom of the E-plates, was automatically calculated for each E-plate well using RTCA software version 1.2 (Roche Diagnostics, Basel, Switzerland) and graphs were generated in real-time using the iCELLigence™ system ([@b30-mmr-16-03-2636],[@b31-mmr-16-03-2636]). Each treatment was performed in duplicate and three independent experiments were conducted.

### Scratch-wound assay

VECs were seeded into 6-well plates at a density of 2.5×10^5^ cells/well. When the cells had reached 90% confluence, cells were washed twice with PBS and serum-starved in RPMI 1640 medium for 9 h. The confluent cell layer was scratched with a 10 µl pipette tip, detached cells were removed by washing with PBS, and cells were cultured in the presence of 10 µM rosiglitazone, 15 µM T0070907 or 0.1% DMSO, respectively, in RPMI 1640 medium for 24 h. Photomicrographs of the scratch wounds were obtained using an inverted phase-contrast microscope (Olympus Corporation) equipped with a digital camera. The wound width was determined using Image-Pro Plus software version 6.0.

### Tube formation assay

BD Matrigel™ Basement Membrane Matrix (BD Biosciences, Franklin Lakes, NJ, USA) was added into 96-well plates (50 µl/well) and allowed to polymerize at 37°C for 30 min. VECs were serum-starved overnight and seeded into 96-well plates precoated with Matrigel at a density of 2×10^4^ cells/well, in the presence of rosiglitazone (10 µM), T0070907 (15 µM) or 0.1% DMSO. Tube formation images were captured at 6 and 10 h under an inverted microscope (Olympus Corporation) equipped with a digital camera, and data were analyzed using Image-Pro Plus software version 6.0. Differentiation of VECs into capillary-like tubes was assessed by two independent investigators, via counting the number of capillary branches under ×100 magnification in 3 random fields/well. The tube formation index was determined via measuring the length of tubes (≥30 µm) in 3 random fields from each well.

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

VECs were seeded into 6-well plates at a density of 2.5×10^5^ cells/well and cultured in complete medium at 37°C in 5% CO~2~ for 6 h. Cells were then treated with serum free medium supplemented with rosiglitazone (10 µM), T0070907 (15 µM) or 0.1% DMSO at 37°C in a 5% CO~2~ for 24 h. When the cells had reached \>90% confluence, total RNA was extracted from VECs with different treatments using Takara MiniBEST Universal RNA Extraction kit (Takara Biotechnology Co., Ltd., Dalian, China), according to the manufacturer\'s protocol. The quantity and quality of total RNA were determined using the NanoDrop 2000 UV--Vis Spectrophotometer (Thermo Fisher Scientific, Inc., Wilmington, DE, USA). Total RNA (500 ng) was reverse transcribed into cDNA using PrimeScript™ 1st strand cDNA synthesis kit (Takara Biotechnology Co., Ltd.). qPCR results were calculated using absolute quantification with the standard curve method. Fragments of the indicated target genes ([Table I](#tI-mmr-16-03-2636){ref-type="table"}) were ligated into a pMD-T18 vector (Takara Biotechnology Co., Ltd.) to create recombinant plasmids, which were amplified in *E. coli* JM109 cells (Takara Biotechnology Co., Ltd.). qPCR was performed using a SYBR^®^ Premix Ex Taq™ kit (Takara Biotechnology Co., Ltd.) on a StepOne™ Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) under the following conditions: 95°C for 2 min, followed by 40 cycles of 95°C for 5 sec at 60°C for 30 sec, followed by melt curve analysis. The reaction volume was 20 µl, consisting of 10 µl SYBR Premix DimerEraser, 0.4 µl ROX dye, 0.2 µl of each primer (20 µM), 2 µl cDNA templates and water up to 20 µl. The standard curve was obtained using 10-fold serially diluted plasmid samples as templates, with R^2^ values \>0.999. The specific primers used for PCR are presented in [Table I](#tI-mmr-16-03-2636){ref-type="table"}. The data were analyzed using the comparative Cq method and gene expression was normalized to GAPDH ([@b32-mmr-16-03-2636]).

### Western blot analysis

VECs were seeded into 6-well plates at a density of 2.5×10^5^ cells/well and cultured in complete medium at 37°C in 5% CO~2~ for 6 h. Cells were then treated with serum free medium supplemented with rosiglitazone (10 µM), T0070907 (15 µM) or 0.1% DMSO at 37°C in a 5% CO~2~ for 24 h. When the cells had reached \>90% confluence, all treated cells were lysed at 4°C for 30 min in radioimmunoprecipitation assay lysis buffer (Bio-Rad Laboratories, Inc., Hercules, CA, USA) containing proteinase inhibitor cocktail (aprotinin and phenylmethanesulfonyl fluoride). Protein concentration was determined using a Bicinchoninic Acid assay with an Easy II Protein Quantitative kit (Beijing Transgen Biotech Co., Ltd., Beijing, China). Equal amounts of extracted protein samples (30 µg) were separated by 10% SDS-PAGE and transferred onto nitrocellulose membranes. The membranes were blocked with 2% bovine serum albumin at RT for 2 h and then incubated with an anti-PPARγ antibody (1:1,000) (cat no. ab19481; Abcam, Cambridge, UK) or anti-GAPDH antibody (1:2,000) (cat no. ab9484; Abcam) overnight at 4°C. Subsequently, membranes were incubated with the HRP-conjugated Affinipure Goat Anti-Rabbit IgG (1:5,000; cat no. SA00001-2, Wuhan Sanying Biotechnology, Wuhan, China). Protein bands were visualized by enhanced chemiluminescence using SuperSignal™ West Pico Chemiluminescent Substrate (Thermo Fisher Scientific, Inc.) on a ChemiDoc™ XRS+ system (Bio-Rad Laboratories, Inc.). PPARγ blots were normalized to GAPDH and semi-quantified by densitometry using ImageJ software (v2.1.4.7; National Institutes of Health, Bethesda, MD, USA).

### Statistical analysis

Data are presented as the mean ± standard error of at least 3 independent experiments. The statistical significance of the differences between groups was assessed using one-way analysis of variance. Statistical analysis was performed using SPSS software version 19.0 (IBM Corp., Armonk, NY, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Morphological and biochemical characteristics of VECs

As presented in [Fig. 1](#f1-mmr-16-03-2636){ref-type="fig"}, isolated VECs grew as confluent monolayers with typical cobblestone morphology, and had ovoid nuclei with 1 or 2 nucleoli. The VEC markers vWF- and CD31 were positively stained in the nuclei ([Fig. 1](#f1-mmr-16-03-2636){ref-type="fig"}). No specific staining was detected in negative control cells.

### Roles of PPARγ in VEC adhesion and proliferation

In the present study, the mRNA and protein expression levels of PPARγ were revealed to be upregulated in VECs following treatment with the PPARγ agonist rosiglitazone, whereas they were downregulated following treatment with the antagonist T007097 ([Fig. 2](#f2-mmr-16-03-2636){ref-type="fig"}). A cellular impedance assay demonstrated that following treatment with rosiglitazone, the adhesive and proliferative capabilities of VECs were enhanced, whereas treatment with T0070907 suppressed VEC adhesion and proliferation ([Fig. 3](#f3-mmr-16-03-2636){ref-type="fig"}).

### Roles of PPARγ in VEC migration

The migratory capabilities of VECs were investigated using a wound healing assay, as previously described ([@b33-mmr-16-03-2636]). As presented in [Fig. 4](#f4-mmr-16-03-2636){ref-type="fig"}, VEC migration was significantly enhanced following treatment with rosiglitazone for 24 h compared with control cells (P\<0.05). Inhibition of PPARγ with T0070907 was revealed to decrease the migratory activity of VECs (P\<0.01).

### Roles of PPARγ in VEC capillary-like tube formation

A tube-formation assay was performed to investigate the roles of PPARγ on the angiogenic potential of VECs. As demonstrated in [Fig. 5A](#f5-mmr-16-03-2636){ref-type="fig"}, following 6 h of culture on Matrigel-coated substrates, VECs exhibited capillary-like tubular structures when observed under a phase-contrast microscope. The quantitative parameters of angiogenesis, including the number of total tubes, total tube length, total branching points and total loops, were revealed to be potentiated following treatment of VECs with rosiglitazone for 6 and 10 h compared with control cells (P\<0.05; [Fig. 5B-E](#f5-mmr-16-03-2636){ref-type="fig"}). Notably, treatment with T0070907 for 6 and 10 h also resulted in a significant increase in tube, loop and branching point numbers, and in tube length compared with the control group (P\<0.01; [Fig. 5B-E](#f5-mmr-16-03-2636){ref-type="fig"}).

### Angiogenic factor expression

The mRNA expression levels of several angiogenic factors were investigated using RT-qPCR in VECs following treatment with rosiglitazone and T0070907. As presented in [Fig. 6A](#f6-mmr-16-03-2636){ref-type="fig"}, the mRNA expression levels of HIF1α and HIF2α were significantly upregulated following treatment with rosiglitazone, whereas they were significantly downregulated following treatment with T0070907.

Treatment with rosiglitazone and T0070907 resulted in the significant downregulation of PlGF and VEGF120 mRNA expression; however, the VEGF188 mRNA levels were significantly upregulated following treatment with rosiglitazone, whereas they remained unaltered following PPARγ inhibition ([Fig. 6B](#f6-mmr-16-03-2636){ref-type="fig"}). Furthermore, the modulation of PPARγ activation did not appear to exert an effect on VEGF164 mRNA expression levels ([Fig. 6B](#f6-mmr-16-03-2636){ref-type="fig"}).

PPARγ inhibition resulted in the significant upregulation of FLT1 expression, whereas PPARγ activation had no effect on FLT1 mRNA levels ([Fig. 6C](#f6-mmr-16-03-2636){ref-type="fig"}). Following treatment with rosiglitazone, the mRNA expression levels of KDR were significantly increased, whereas T0070907 was demonstrated to suppress KDR expression ([Fig. 6C](#f6-mmr-16-03-2636){ref-type="fig"}). Conversely, the mRNA expression levels of sFlt1 were significantly downregulated in rosiglitazone-treated VECs, and significantly upregulated following T0070907 administration ([Fig. 6C](#f6-mmr-16-03-2636){ref-type="fig"}).

The mRNA expression levels of Ang-1 in VECs were significantly enhanced following PPARγ activation, and significantly suppressed in T0070907-treated cells ([Fig. 6D](#f6-mmr-16-03-2636){ref-type="fig"}). However, Ang-2 mRNA expression was consistently decreased following PPARγ activation and blockade ([Fig. 6D](#f6-mmr-16-03-2636){ref-type="fig"}).

Discussion
==========

In a previous study, the PPARγ agonist troglitazone exhibited species-specific effects in human and mouse endothelial cells, as it was reported to increase the proliferation and survival of mouse mammary fat pad microvascular endothelial cells, whereas it did not affect human dermal microvascular endothelial cells ([@b34-mmr-16-03-2636]). In the present study, the PPARγ agonist rosiglitazone was revealed to enhance the adhesive, proliferative and migratory capabilities of porcine VECs; conversely, the PPARγ antagonist T0070907 inhibited VEC adhesion, proliferation and migration. These results suggested that PPARγ may exert proangiogenic effects during porcine placental development. In accordance with a previous study reporting dysregulation of placental layers and vasculature defects in PPARγ^−/−^ mice ([@b20-mmr-16-03-2636]), the present findings suggested that PPARγ may promote placental vascularization in porcine VECs, possibly via enhancing VEC differentiation, proliferation and energy metabolism.

Currently, the role of PPARγ during angiogenesis remains controversial. Previous studies have suggested that PPARγ activation may inhibit angiogenesis, as demonstrated by the inhibition of capillary-like tube formation in human retinal pigment epithelial and bovine choroidal endothelial cells ([@b35-mmr-16-03-2636]), and by the suppression of the proliferative and migratory capabilities of human umbilical vein endothelial cells ([@b36-mmr-16-03-2636],[@b37-mmr-16-03-2636]). However, contradictory studies have suggested proangiogenic effects for PPARγ, exerted through the regulation of VEGF expression in myocardial ([@b38-mmr-16-03-2636]) and pulmonary capillary cells ([@b39-mmr-16-03-2636]). These discrepancies may be attributed to inter-species and cell type-specific differences, and the different types and doses of PPARγ ligands that were used in the various studies. Notably, in the present study, the quantitative parameters of angiogenesis appeared to be invariably enhanced following the activation and inhibition of PPARγ in VECs. These effects may be associated with the various VEGF isoforms and their receptors: PlGF and VEGF120 mRNA expression levels were downregulated following PPARγ activation and blockade; however, PPARγ activation may promote tube formation through the potentiation of VEGF188/KDR signaling. Conversely, PPARγ blockade may enhance capillary-like tube formation via promoting VEGF164/FLT1 and VEGF188/FLT1 signaling.

Angiogenesis is an adaptive response to hypoxia *in vivo* and *in vitro*, and HIFs are the key mediators responsible for the activation of several angiogenic factors, including VEGFA ([@b40-mmr-16-03-2636]). However, the various HIF isoforms may be characterized by differential expression and distinct functions ([@b41-mmr-16-03-2636]). In the present study, the mRNA expression levels of HIF1α and HIF2α were modulated by PPARγ activation or inhibition, indicating that HIF and PPARγ were both involved in the recruitment of growth factors and induction of vascularization. Therefore, VEC adhesion, proliferation and migration may be modified by the synergistic effect of HIF and PPARγ.

Three stable VEGFA isoforms, namely VEGF120, VEGF164 and VEGF188, have been identified in the porcine peri-implantation conceptus ([@b14-mmr-16-03-2636],[@b42-mmr-16-03-2636]). VEGFA has been implicated in angiogenesis; however, the various VEGFA isoforms are characterized by distinct properties and expression patterns ([@b43-mmr-16-03-2636]). In addition, the VEGFA isoforms differ with regard to their binding affinity for the various VEGFR subtypes ([@b14-mmr-16-03-2636],[@b43-mmr-16-03-2636]). In the present study, three VEGF isoforms, namely PlGF, VEGF120 and VEGF188, were revealed to be modulated by PPARγ activation or inhibition; whereas VEGF164 did not appear to be affected by PPARγ modulation. These results may indicate that PPARγ mediates vascularization through the modulation of VEGF120/VEGFRs, VEGF188/VEGFRs and PlGF/VEGFRs, similarly with the situation observed during early pregnancy in the pig ([@b42-mmr-16-03-2636],[@b44-mmr-16-03-2636]). These results suggested that various VEGF isoforms and VEGFR subtypes may be differentially implicated in the various stages of the angiogenic process, and may differentially regulate vascularization.

In present study, the mRNA expression levels of Ang-1 and Ang-2 were assessed in VECs, as has previously been reported in perivascular and endothelial tip cells ([@b45-mmr-16-03-2636]). The balance between Ang-1 and Ang-2 is critical for vascular stability, and Ang-1/Ang-2 imbalance has been associated with vascular disruption and the initiation of angiogenesis in tumor tissues ([@b46-mmr-16-03-2636]). In addition, aberrant angiogenesis has been reported in Ang-1^−/−^ mice ([@b47-mmr-16-03-2636]). In the present study, PPARγ modulation was demonstrated to exert distinct effects on Ang-1 and Ang-2 mRNA expression, whereby PPARγ activation significantly upregulated Ang-1 and downregulated Ang-2.

In conclusion, the present results suggested that PPARγ may bind to a PPAR-responsive element in the VEGFA promoter region ([@b23-mmr-16-03-2636]), and promote the translation of the VEGF188 isoform instead of VEGF120 or VEGF164, thus promoting VEGFA/KDR and VEGFA/Flt1 interactions, and increasing capillary density and the total number of capillary-like tubes. Furthermore, PPARγ may interact with HIFs and thus activate VEGF transcription. Therefore, the present findings suggested that PPARγ may be implicated in angiogenesis, through the promotion of endothelial cell adhesion, proliferation and migration, and through enhancing the formation and the stability of capillary-like tubules. However, further studies are required to elucidate the detailed molecular mechanisms that underlie the involvement of PPARγ in angiogenic processes.
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![Immunofluorescent staining of VECs. The expression of vWF and CD31, indicated by red fluorescence, was observed in VECs with a fluorescent microscope under ×400 magnification. DAPI was used to stain the cell nuclei. NC VECs were stained with negative serum instead of primary antibodies. VEC, vascular endothelial cell; vWF, von Willebrand factor; CD, cluster of differentiation; NC, negative control.](MMR-16-03-2636-g00){#f1-mmr-16-03-2636}

![PPARγ expression in VECs following treatment with the PPARγ agonist rosiglitazone and the antagonist T0070907. (A) PPARγ mRNA expression levels were assessed using reverse transcription-quantitative polymerase chain reaction. (B) Western blot analysis of PPARγ protein expression levels. GAPDH served as an internal control. (C) Blots were semi-quantified using densitometry. NC cells were treated with dimethyl sulfoxide. Data are presented as the mean ± standard error of at least 3 independent experiments. \*P\<0.05, \*\*P\<0.01 vs. NC. PPAR, peroxisome proliferator-activated receptor; VEC, vascular endothelial cell; NC, negative control; R, rosiglitazone; T, T0070907.](MMR-16-03-2636-g01){#f2-mmr-16-03-2636}

![Effects of rosiglitazone and T0070907 on the adhesive and proliferative capabilities of VECs. VECs were treated with the PPARγ agonist rosiglitazone and the antagonist T0070907. NC cells were treated with dimethyl sulfoxide. Cellular impedance assays were used to evaluate VEC (A) adhesion and (B) proliferation. Data are presented as the mean ± standard error of at least 3 independent experiments. \*P\<0.05, \*\*P\<0.01 vs. NC. VEC, vascular endothelial cell; PPAR, peroxisome proliferator-activated receptor; NC, negative control; R, rosiglitazone; T, T0070907.](MMR-16-03-2636-g02){#f3-mmr-16-03-2636}

![Effects of rosiglitazone and T0070907 on the migratory capabilities of VECs. VECs were treated with the PPARγ agonist rosiglitazone and the antagonist T0070907 and cellular migration was evaluated using a scratch-wound assay. NC cells were treated with dimethyl sulfoxide. (A) Representative photomicrographs of the wounded VEC monolayer immediately following the scratch (0 h) and following 24 h of treatment with rosiglitazone or T0070907. Magnification, ×100. (B) The migration distance of VECs was analyzed following 24 h of treatment with rosiglitazone or T0070907. \*P\<0.05, \*\*P\<0.01 vs. NC. VEC, vascular endothelial cell; PPAR, peroxisome proliferator-activated receptor; NC, negative control; R, rosiglitazone; T, T0070907.](MMR-16-03-2636-g03){#f4-mmr-16-03-2636}

![Effects of rosiglitazone and T0070907 on the tube-formation capabilities of VECs. VECs were treated with the PPARγ agonist rosiglitazone and the antagonist T0070907 and tube formation was following 6 and 10 h of treatment. NC cells were treated with dimethyl sulfoxide. (A) Representative photomicrographs were captured under ×100 magnification. Quantitative parameters of tube formation were statistically analyzed: (B) Number of total tubes, (C) total tube length, (D) total number of branching points, (E) total number of loops. Data are presented as the mean ± standard error of at least 3 independent experiments. \*P\<0.05, \*\*P\<0.01 vs. NC. VEC, vascular endothelial cell; PPAR, peroxisome proliferator-activated receptor; NC, negative control; R, rosiglitazone; T, T0070907.](MMR-16-03-2636-g04){#f5-mmr-16-03-2636}

![Effects of rosiglitazone and T0070907 on mRNA expression of angiogenic factors in VECs. VECs were treated with the PPARγ agonist rosiglitazone and the antagonist T0070907. mRNA expression levels of (A) HIFs, (B) VEGF isoforms, (C) VEGFR subtypes and (D) Ang subtypes were assessed using reverse transcription-quantitative polymerase chain reaction following 24 h of treatment. NC cells were treated with dimethyl sulfoxide. Data are presented as the mean ± standard error of at least 3 independent experiments. \*P\<0.05, \*\*P\<0.01 vs. NC. VEC, vascular endothelial cell; PPAR, peroxisome proliferator-activated receptor; HIF, hypoxia-inducible factor; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; Ang, angiopoietin; NC, negative control; R, rosiglitazone; T, T0070907; PlGF, placental growth factor; FLT1, VEGFR subtype 1; KDR, VEGFR subtype 2; sFlt1, soluble fms-like tyrosine kinase-1.](MMR-16-03-2636-g05){#f6-mmr-16-03-2636}

###### 

Primer sequences and standard curves used in reverse transcription-quantitative polymerase chain reaction.

  Gene      Sequence                            Length (bp)   Standard equation     Reference sequence
  --------- ----------------------------------- ------------- --------------------- --------------------
  HIF1α     F: 5′-TTTTACTCATCCGTGCGACCAT-3′     276           y=−3.3524*x*+40.046   EF070345.1
            R: 5′-GGTTCACAAATCAGCACCAAGC-3′                   R^2^=0.9999           
  HIF2α     F: 5′-TGGAGGGTTTCATTGCCGTAG-3′      287           y=−3.3795*x*+36.417   EF375723.1
            R: 5′-CCAGGTGGCTGACTTGAGGTT-3′                    R^2^=0.9995           
  PPARγ     F: 5′-TTATGGAGCCCAAGTTTGAGTTT-3′    159           y=−3.2544*x*+38.805   KM382175.1
            R: 5′-CTTGTAGCAGGTTGTCTTGAATG-3′                  R^2^=0.999            
  VEGF120   F: 5′-AAGGCCAGCACATAGGAGAG-3′       101           y=−3.0243*x*+37.267   KJ729036
            R: 5′-CCTCGGCTTGTCACATTTTT-3′                     R^2^=0.9997           
  VEGF164   F: 5′-GAGGCAAGAAAATCCCTGTG-3′       150           y=−3.125*x*+36.848    
            R: 5′-TCACATCTGCAAGTACGTTCG-3′                    R^2^=0.9995           
  VEGF188   F: 5′-GGAGACCAGAAACCCCACGAAGT-3′    224           y=−3.2817*x*+37.074   
            R: 5′-ATAATCTGCATGGCGATGTTGAA-3′                  R^2^=0.9997           
  PlGF      F: 5′-GCTGGTGGACATCGTGTCTGTG-3′     258           y=−3.3724*x*+36.761   FJ177137.1
            R: 5′-CCGCACCTTTCTGGCTTCATCT-3′                   R^2^=0.9993           
  FLT1      F: 5′-CACCCCGGAAATCTATCAGATC-3′     168           y=−3.0964*x*+37.958   XM001925740.6
            R: 5′-GAGTACGTGAAGCCGCTGTTG-3′                    R^2^=0.9994           
  KDR       F: 5′-GATGCTCGCCTCCCTTTGA-3′        180           y=−3.1662*x*+37.922   XM003128987.4
            R: 5′-AGTTCCTTCTTTCAGTCGCCTACA-3′                 R^2^=0.9993           
  sFlt1     F: 5′-TGAGCACTGCAACAAAAAGG-3′       168           y=−3.3005*x*+38.014   FJ263097.1
            R: 5′-CCGAGCCTGAAAGTTAGCAA-3′                     R^2^=0.9993           
  Ang-1     F: 5′-GCCATAACCAGTCAGAGGCAGTA-3′    184           y=−3.22*x*+37.737     AF233227.1
            R: 5′-AATCAGCACCATGTAAGATCAGG-3′                  R^2^=0.9994           
  Ang-2     F: 5′-CCAGGTGTTAGTATCCAAGCAAA-3′    265           y=−3.3733*x*+39.653   AF233228.1
            R: 5′-GTTAGGAAAGGTCAGCGTGTAGG-3′                  R^2^=0.9995           
  GAPDH     F: 5′-ACAGGGTGGTGGACCTCATG-3′       178           y=−3.3734*x*+38.727   AK234838.1
            R: 5′-GGGTCTGGGATGGAAACTGG-3′                     R^2^=0.999            

HIF, hypoxia inducible factor; PPAR, peroxisome proliferator-activated receptor; VEGF, vascular endothelial growth factor; PlGF, placental growth factor; FLT1, VEGF receptor subtype 1; KDR, VEGF receptor subtype 2; sFlt1, soluble fms-like tyrosine kinase-1; Ang, angiopoietin; F, forward primer; R, reverse primer.
